Jefferies Maintains Buy on Arbutus Biopharma, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Dennis Ding maintains a Buy rating on Arbutus Biopharma and raises the price target from $5 to $7.
September 05, 2024 | 11:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies analyst Dennis Ding has reaffirmed a Buy rating for Arbutus Biopharma and increased the price target from $5 to $7, indicating a positive outlook for the company's stock.
The increase in the price target from $5 to $7 by Jefferies suggests a positive outlook for Arbutus Biopharma, likely leading to a short-term increase in stock price. The reaffirmation of the Buy rating further supports investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100